Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

White House Using PBM Buzz To Diffuse Price Control Criticisms

Executive Summary

The White House is substituting pharmacy benefit managers for price controls as the rhetorical centerpiece of the Administration's second attempt to provide government prescription drug coverage to seniors.

You may also be interested in...



Breaux/Thomas Compromise With Clinton Could Begin At $90 Bil. For Drugs

A $90 bil. allocation over 10 years could be enough for a workable political compromise for the start-up of a Medicare drug benefit, Progressive Policy Institute Senior Economist Jeff Lemieux suggested at a Capitol Hill forum Sept. 13.

Breaux/Thomas Compromise With Clinton Could Begin At $90 Bil. For Drugs

A $90 bil. allocation over 10 years could be enough for a workable political compromise for the start-up of a Medicare drug benefit, Progressive Policy Institute Senior Economist Jeff Lemieux suggested at a Capitol Hill forum Sept. 13.

Kennedy PBM Bill Has Embedded Price Controls, PhRMA Tells Finance Cmte.

Benchmark pricing provisions in Sen. Kennedy's (D-Mass.) pharmacy benefit management-based Medicare drug benefit proposal would represent de facto government price controls, Pharmaceutical Research & Manufacturers of America President Alan Holmer said in testimony to the Senate Finance Committee.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS034458

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel